A Simple and Rapid UPLC‐UV Method for Detecting DPD Deficiency in Patients With Cancer
Authors:
Open Access
- 14 February 2020
- journal article
- research article
- Published by Wiley in Clinical and Translational Science
- Vol. 13 (4) , 761-768
Abstract
Detecting patients with DPD deficiency is becoming a major concern in clinical oncology. Monitoring physiological plasma uracil and/or plasma uracil‐to‐dihydrouracil metabolic ratio is a common surrogate frequently used to determine DPD phenotype without direct measurement of the enzymatic activity. With respect to the rising number of patients to be analyzed, developing simple, rapid and affordable methods suitable to routine screening is critical. We have developed and validated a simple and robust UPLC‐UV method with shorten (i.e., 12 minutes) analytical run times, compatible with these requirements of large‐scale upfront screening. The method enabled detection of U over a 5‐500 ng.mL‐1 range (265 nm) and of UH2 over a 40‐500 ng.mL‐1 range (210 nm) in plasma with no chromatographic interference. When used as part of routine screening for DPD deficiency, this method was fully able to discriminate non‐deficient patients (i.e., with U levels below 16 ng.mL‐1) from deficient patients at risk of severe toxicities (i.e., U > 16 ng.mL‐1). Results from one month of routine testing are presented and although no complete deficit were detected, 10,7% of the screened patients presented DPD deficiency and would thus require cut in dosing. Overall, this new method, using a simple pre‐analytical solid‐phase extraction procedure and based upon the use of standard UPLC apparatus is both cost‐ and time‐effective and can be easily implemented at low cost in any laboratory about to start DPD testing in routine.Keywords
This publication has 32 references indexed in Scilit:
- Pretherapeutic uracil and dihydrouracil levels in saliva of colorectal cancer patients are associated with toxicity during adjuvant 5-fluorouracil-based chemotherapyCancer Chemotherapy and Pharmacology, 2014
- Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiencyThe Pharmacogenomics Journal, 2013
- Validation of an Ultra-High Performance Liquid Chromatography Tandem Mass Spectrometric Method for Quantifying Uracil and 5,6-Dihydrouracil in Human PlasmaJournal of Chromatographic Science, 2012
- Routine Dihydropyrimidine Dehydrogenase Testing for Anticipating 5-Fluorouracil–Related Severe Toxicities: Hype or Hope?Clinical Colorectal Cancer, 2010
- A Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of 5-Fluorouracil Degradation Rate by Intact Peripheral Blood Mononuclear CellsTherapeutic Drug Monitoring, 2009
- Profiling Dihydropyrimidine Dehydrogenase Deficiency in Patients with Cancer Undergoing 5-Fluorouracil/Capecitabine TherapyClinical Colorectal Cancer, 2006
- A Rapid and Inexpensive Method for Anticipating Severe Toxicity to Fluorouracil and Fluorouracil-based ChemotherapyTherapeutic Drug Monitoring, 2006
- The Uracil Breath Test in the Assessment of Dihydropyrimidine Dehydrogenase Activity: Pharmacokinetic Relationship between Expired 13CO2 and Plasma [2-13C]DihydrouracilClinical Cancer Research, 2006
- An accurate dihydrouracil/uracil determination using improved high performance liquid chromatography method for preventing fluoropyrimidines-related toxicity in clinical practiceJournal of Chromatography B, 2005
- Automated screening system for purine and pyrimidine metabolism disorders using high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1995